Your browser doesn't support javascript.
loading
Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody.
Broughton, Sophie E; Hercus, Timothy R; Hardy, Matthew P; McClure, Barbara J; Nero, Tracy L; Dottore, Mara; Huynh, Huy; Braley, Hal; Barry, Emma F; Kan, Winnie L; Dhagat, Urmi; Scotney, Pierre; Hartman, Dallas; Busfield, Samantha J; Owczarek, Catherine M; Nash, Andrew D; Wilson, Nicholas J; Parker, Michael W; Lopez, Angel F.
Afiliação
  • Broughton SE; Australian Cancer Research Foundation Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, VIC 3065, Australia.
  • Hercus TR; The Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, SA 5000, Australia.
  • Hardy MP; CSL Limited, Parkville, VIC 3010, Australia.
  • McClure BJ; The Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, SA 5000, Australia.
  • Nero TL; Australian Cancer Research Foundation Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, VIC 3065, Australia.
  • Dottore M; The Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, SA 5000, Australia.
  • Huynh H; CSL Limited, Parkville, VIC 3010, Australia.
  • Braley H; CSL Limited, Parkville, VIC 3010, Australia.
  • Barry EF; The Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, SA 5000, Australia.
  • Kan WL; The Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, SA 5000, Australia.
  • Dhagat U; Australian Cancer Research Foundation Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, VIC 3065, Australia.
  • Scotney P; CSL Limited, Parkville, VIC 3010, Australia.
  • Hartman D; CSL Limited, Parkville, VIC 3010, Australia.
  • Busfield SJ; CSL Limited, Parkville, VIC 3010, Australia.
  • Owczarek CM; CSL Limited, Parkville, VIC 3010, Australia.
  • Nash AD; CSL Limited, Parkville, VIC 3010, Australia.
  • Wilson NJ; CSL Limited, Parkville, VIC 3010, Australia. Electronic address: nick.wilson@csl.com.au.
  • Parker MW; Australian Cancer Research Foundation Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, VIC 3065, Australia; Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, VIC 3010, Austra
  • Lopez AF; The Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, SA 5000, Australia. Electronic address: angel.lopez@health.sa.gov.au.
Cell Rep ; 8(2): 410-9, 2014 Jul 24.
Article em En | MEDLINE | ID: mdl-25043189
ABSTRACT
Interleukin-3 (IL-3) is an activated T cell product that bridges innate and adaptive immunity and contributes to several immunopathologies. Here, we report the crystal structure of the IL-3 receptor α chain (IL3Rα) in complex with the anti-leukemia antibody CSL362 that reveals the N-terminal domain (NTD), a domain also present in the granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-5, and IL-13 receptors, adopting unique "open" and classical "closed" conformations. Although extensive mutational analyses of the NTD epitope of CSL362 show minor overlap with the IL-3 binding site, CSL362 only inhibits IL-3 binding to the closed conformation, indicating alternative mechanisms for blocking IL-3 signaling. Significantly, whereas "open-like" IL3Rα mutants can simultaneously bind IL-3 and CSL362, CSL362 still prevents the assembly of a higher-order IL-3 receptor-signaling complex. The discovery of open forms of cytokine receptors provides the framework for development of potent antibodies that can achieve a "double hit" cytokine receptor blockade.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Subunidade alfa de Receptor de Interleucina-3 / Anticorpos Monoclonais Humanizados / Antineoplásicos Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Subunidade alfa de Receptor de Interleucina-3 / Anticorpos Monoclonais Humanizados / Antineoplásicos Idioma: En Ano de publicação: 2014 Tipo de documento: Article